‘Be wary of prescribing’ tirzepatide amid another diabetes drug shortage
The shortage was sparked by off-label prescribing for weight loss, the TGA said.
Doctors should exercise caution when prescribing tirzepatide, a leading GP says, after a surge in demand sparked a supply shortage within two months of entering the Australian private market.
Drug sponsor Eli Lilly recently notified the TGA that multiple doses of the subcutaneous injectable glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist (RA) were already unavailable since its September launch.
The affected tirzepatide (Mounjaro) doses include the following:
Supplies of the 12.5mg and 15mg doses were also limited, with full availability of all strengths expected to return by September 2024.
